Table 2.
Summary of TEAEs (up to week 24)
| Data presented as n (%) | FIL 200 mg (n = 38) | LANRA 30 mg (n = 37) | TIRA 40 mg (n = 39) | PBO (n = 36) |
|---|---|---|---|---|
| Any TEAE | 32 (84.2) | 29 (78.4) | 29 (74.4) | 27 (75.0) |
| TEAE related to study drug | 10 (26.3) | 10 (27.0) | 5 (12.8) | 6 (16.7) |
| TEAE ≥ Grade 3 | 3 (7.9) | 4 (10.8) | 1 (2.6) | 2 (5.6) |
| TEAE related to study drug ≥ Grade 3 | 2 (5.3) | 0 | 0 | 1 (2.8) |
| TE serious AE | 3 (7.9) | 3 (8.1) | 1 (2.6) | 2 (5.6) |
| TE serious AE related to study drug | 1 (2.6) | 0 | 0 | 0 |
| TEAE leading to premature discontinuation of study drug | 4 (10.5) | 7 (18.9) | 0 | 0 |
| TEAE leading to premature discontinuation of study | 1 (2.6) | 5 (13.5) | 0 | 0 |
| Death | 0 | 0 | 0 | 0 |
TEAEs are AEs that began on/after the treatment start date and ≤30 days after last dose of study drug or led to premature treatment discontinuation. AE: adverse event; FIL: filgotinib; LANRA: lanraplenib; PBO: placebo; TE: treatment-emergent; TEAE: treatment-emergent adverse event; TIRA: tirabrutinib.